September 2017 ICBI UPDATE ON THE ROAD TO THE CURE

By Ram Bhatt, PhD
ICBII continues looking ……. to BRING THIS SCIENCE TO THE PEOPLE.

The scientists at ICB International, Inc., (“ICBII”), are working hard to generate more of the α-synuclein-SMART Molecule (α-syn-SM), a potential drug for Parkinson’s disease, to fulfill their obligations for ongoing collaborations with a Canadian University, a US pharmaceutical company and a California University. The successful conclusion to all of this could lead to a long-term relationship with a US pharmaceutical Company and expedite the process of the Investigational New Drug Application to the FDA.

The most challenging of these three collaborations is that, at this time, all of the α-synuclein-SMART Molecules have to be developed by hand. This painstaking procedure takes a tremendous amount of time and money.

Looking at the bright side, when this technology is validated three times over – mind you, it’s already been proven to work in mice – As we said earlier, ICBII can begin the process of its Investigational New Drug application with the FDA.

We may have told you that we currently are in discussions with five big pharmaceutical companies, most of whom are waiting for the humanized form of the drug that is ready for human use before coming forth with their proposals to partner and license the Parkinson’s SMART Molecule.

One of these pharmaceutical companies wants to replicate this technology at their headquarters before initiating business talks. Unfortunately, in the last year, this pharmaceutical company has experienced internal problems and was forced to downsize. However, with their situation stabilizing, their scientists are showing great interest and enthusiasm to carry out a validation experiment. ICBII is doing all that it can to produce adequate amounts of its drug for this and the other validation experiments.

The SMS technology has shown tremendous potential in animals to detect and therapeutically correct the levels of pathological protein alpha-synuclein in their brain. The Company believes it has the drug to potentially halt Parkinson’s disease in humans.

As we’ve said before, this is “real-time science reporting” so we tell you that for human testing, the drug (SM) has to be humanized, a process required by the FDA which can easily take one year. As mentioned above, some of the pharmaceutical companies that we have been talking to would like to see humanized α-syn-SM that is ready for human use before entering into business discussions. ICBII continues looking for funding from Angel Investors, Investment Bankers, etc. to BRING THIS SCIENCE TO THE PEOPLE.

            HOW CAN YOU HELP? The joy of being a part of this historical event can be had by helping ICBI find the funds to bring these trials to fruition through your personal, including your IRA, investment, and/or by finding others with the financial ability and humanitarian mindset to accomplish the – until now – impossible. Please contact Jo Rosen at Parkinson’s Resource Organization 760-773-5628 or jorosen@Parkinsonsresource.org or by contacting ICBI directly through their website http://icbii.com/ or by phone 858-455-9880.

IMAGINE the world without Parkinson’s, MSA or Alzheimer’s disease. JUST IMAGINE.

Mark your calendars and join us at the Parkinson’s Resource Organization “ON THE ROAD TO THE CURE” a Parkinson’s Health and Wellness Symposium October 28th in Palm Desert, CA

About Editor